Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients.
[familial mediterranean fever]
Coagulation
abnormalities
have
been
reported
in
familial
Mediterranean
fever
(
FMF
)
patients
with
amyloidosis
and
nephrotic
syndrome
;
but
there
is
not
enough
data
about
the
continuity
of
the
thrombogenic
activity
in
FMF
patients
in
clinical
remission
.
The
purpose
of
this
study
was
to
assess
thrombin
activatable
fibrinolysis
inhibitor
(
TAFI
)
levels
and
its
relationship
with
fibrinolytic
activity
and
also
evaluate
relationships
between
mutations
and
clinical
signs
in
attack-free
patients
without
amyloidosis
.
Seventy
-
nine
FMF
patients
and
40
healthy
adults
were
included
.
The
study
group
was
divided
into
five
groups
as
follows
:
first
group
,
homozygote
M
694
V
;
second
group
,
homozygote
M
680
I
;
third
group
,
M
694
V
in
one
allele
,
the
other
allele
have
other
mutations
or
not
;
fourth
group
,
other
mutations
;
and
fifth
group
,
no
mutation
.
Serum
TAFI
levels
were
significantly
increased
in
patients
compared
with
healthy
individuals
(
116
.
64
 
±
 
21
.
8
vs
.
78
.
48
 
±
 
19
.
7
 
μg
/
mL
,
p
 
<
 
0
.
001
)
and
a
positive
correlation
was
detected
between
TAFI
antigen
level
and
erythrocyte
sedimentation
rate
and
C-
reactive
protein
levels
(
r
 
=
 
0
.
247
,
p
 
=
 
0
.
029
and
r
 
=
 
0
.
252
,
p
 
=
 
0
.
032
,
respectively
)
.
Mean
fibrinogen
and
TAFI
levels
were
significantly
higher
in
Group
1
than
the
other
groups
(
p
 
=
 
0
.
04
and
p
 
=
 
0
.
001
,
respectively
)
and
in
Group
3
it
was
higher
than
Groups
2
,
4
and
5
(
p
 
=
 
0
.
04
and
p
 
=
 
0
.
001
,
respectively
)
.
High
level
of
TAFI
antigen
in
attack-free
period
of
FMF
disease
shows
ongoing
subclinical
inflammation
and
hypercoagulability
.
Clinicians
should
be
careful
about
thrombosis
even
in
patients
at
clinical
remission
.
Also
,
genetic
tests
must
be
considered
to
predict
clinical
outcome
and
to
reduce
complications
of
FMF
disease
.
Diseases
Validation
Diseases presenting
"fever"
symptom
22q11.2 deletion syndrome
acute rheumatic fever
alexander disease
allergic bronchopulmonary aspergillosis
canavan disease
carcinoma of the gallbladder
child syndrome
congenital toxoplasmosis
cushing syndrome
cystinuria
dracunculiasis
erdheim-chester disease
esophageal adenocarcinoma
esophageal carcinoma
familial mediterranean fever
focal myositis
hodgkin lymphoma, classical
lamellar ichthyosis
legionellosis
locked-in syndrome
malignant atrophic papulosis
neonatal adrenoleukodystrophy
neuralgic amyotrophy
oculocutaneous albinism
papillon-lefèvre syndrome
pyomyositis
pyruvate dehydrogenase deficiency
scrub typhus
severe combined immunodeficiency
sneddon syndrome
systemic capillary leak syndrome
triple a syndrome
typhoid
waldenström macroglobulinemia
wolf-hirschhorn syndrome
This symptom has already been validated